Solana Takes a $280M Hit, Cannabis Stocks Bleed, and the Brain Keeps Healing

The Weedcoin Team

This was a week that tested everything. A $280 million exploit on the Drift protocol rattled the Solana ecosystem. Cannabis stocks continued their freefall under tariff pressure and rescheduling uncertainty. And in a research lab, scientists published findings that could change how we treat the most devastating injuries the human brain can suffer.

The markets are messy. The politics are stuck. The science keeps moving. That is where we are.

The Drift Exploit: What Happened to Solana

A social engineering attack on the Drift protocol -- one of Solana's largest decentralized exchanges -- resulted in the theft of over $280 million this week. The attacker did not exploit a smart contract vulnerability. Instead, they used social engineering and pre-approved transactions to gain full administrative control of the protocol.

What made it worse: blockchain investigator ZachXBT revealed that Circle had a six-hour window to freeze over $230 million in USDC being bridged from Solana to Ethereum. They chose not to act.

SOL dropped to the $78 range, testing the critical $75-$80 support zone. DEX volumes fell 40 percent from January levels. The RSI sits at 34.55 -- oversold territory, but not a guaranteed bounce signal.

For Weedcoin and the broader Solana community, this is a gut-check moment. The exploit was not a failure of Solana's blockchain technology -- the chain itself performed exactly as designed. It was a failure of human operational security at the application layer, and a failure of a centralized stablecoin issuer to act when it mattered.

The distinction matters. Solana's infrastructure -- the Alpenglow upgrade targeting 150-millisecond finality, the Firedancer validator client, the $57 billion in monthly DEX volume, the $650 billion in stablecoin transactions -- none of that broke. What broke was trust in the humans and companies operating on top of it.

Key levels for April: $75 is the line. A daily close below it opens the door to $67 -- the February bottom. Above $86 (the 20-day EMA), the picture changes significantly. Cumulative US spot SOL ETF inflows sit at roughly $980 million, providing an institutional floor that previous cycles lacked.

The Solana Developer Platform, launched this week with Mastercard, Worldpay, and Western Union as early adopters, continues to build the institutional bridge regardless of price action. Stablecoin transaction volume on Solana hit $650 billion in February -- nearly three times January's figure. The network is being used at scale for real financial infrastructure, which is the thesis that matters over months and years, even when a single exploit dominates the weekly narrative.

Cannabis Stocks Under Siege

The cannabis sector is getting hit from every angle simultaneously.

Tariffs: With total duties on Chinese imports at 54 percent, the cost of vape hardware, packaging materials, grow equipment, and extraction machinery has spiked. Companies are absorbing costs they cannot pass to consumers without losing market share to the illicit market.

Tax burden: Section 280E continues to prevent cannabis operators from deducting standard business expenses -- an effective tax rate that can exceed 70 percent. Rescheduling to Schedule III would eliminate 280E, but as we covered yesterday, the DEA process is frozen with no judge and no timeline.

Debt cliff: An estimated $3 billion in cannabis company debt matures by the end of 2026. Schwazze has already defaulted on a $700,000 payment. TILT Holdings received a default notice for over $4 million. Gold Flora announced plans to liquidate assets. The companies that bet their survival on rescheduling happening fast are running out of runway.

Stock performance: Major MSOs including Trulieve, Curaleaf, Cresco Labs, and Green Thumb Industries saw declines of 17 to 39 percent following Trump's December executive order -- a sell-the-news reaction that has not recovered. Canadian producers like Canopy Growth fell 12 percent.

The paradox is sharp: the political environment for cannabis is arguably the most favorable it has ever been (a sitting president signed a rescheduling EO), while the financial environment for cannabis companies is among the worst. The companies are leaner, their cost structures are improved, but the timeline for regulatory relief keeps stretching.

If rescheduling happens in 2026, valuations could reset dramatically upward. If it does not, the debt cliff becomes a mass casualty event.

New Jersey: 9 Days

The April 13 deadline approaches. Nine days until New Jersey redefines legal hemp using total THC calculations and a 0.4 milligram per container cap. Delta-8 gummies, THCA flower, THC-O products -- all reclassified as cannabis and restricted to CRC-licensed dispensaries.

Bill S3945, which could extend the timeline to November, is awaiting the governor's signature. The industry is treating it as upside, not certainty.

For operators, the compliance checklist is a full business overhaul: SKU-level audits against total THC limits, reformulation of any product exceeding 0.4mg per container, updated labeling and certificates of analysis, excise tax registration for intoxicating hemp beverages ($3.75 per gallon), CRC licensing confirmation, and complete staff retraining on the new definitions. Nine days is not a lot of time for all of that.

Brain scan images on a medical monitor with CBD oil bottles in a neurology research setting

CBD and the Injured Brain: What 2026 Research Shows

Today's cannabis benefits section covers neuroprotection and traumatic brain injury -- an area where 2026 research has produced some of the most compelling findings in cannabis science.

A study published in Phytomedicine by researchers at Shengjing Hospital of China Medical University found that CBD significantly reduced cognitive impairment following traumatic brain injury by protecting neurons from oxidative stress and programmed cell death. The research identified a previously unrecognized molecular pathway -- the SET/PP2A/Akt signaling axis -- through which CBD exerts its neuroprotective effects.

Here is what that means in plain language: when the brain is injured, a cascade of oxidative damage and inflammation kills neurons that survived the initial trauma. This secondary injury is what causes much of the lasting cognitive decline after TBI. CBD appears to interrupt that cascade at multiple levels, keeping neurons alive that would otherwise die in the days and weeks following injury.

The mechanism is specific and well-documented. CBD directly binds to the SET protein, triggering structural changes that keep it localized in the cytoplasm. This suppresses PP2A activity, activates the Akt signaling pathway (associated with cell survival), and reduces both oxidative damage and pro-apoptotic signaling. Advanced techniques including RNA sequencing, protein interaction assays, and molecular dynamics simulations confirmed the pathway.

This builds on earlier preclinical evidence reviewed in Frontiers in Neurology showing that CBD's neuroprotective properties include reducing neuroinflammation, scavenging reactive oxygen species, promoting neurogenesis (the growth of new neurons), regulating cerebral blood flow, and protecting the blood-brain barrier from TBI-induced permeability.

A Phase II randomized clinical trial registered on ClinicalTrials.gov is currently testing full-spectrum CBD (with trace THC) versus broad-spectrum CBD (without THC) versus placebo in TBI patients over 12 weeks, measuring cognitive function, anxiety, pain, depression, and sleep outcomes.

For the roughly 2.8 million Americans who sustain a TBI each year -- including hundreds of thousands of military veterans -- the lack of effective treatments for post-injury cognitive decline is a critical unmet need. CBD is not a cure, but the mechanistic evidence for its neuroprotective role is becoming difficult to dismiss.

Congressman Steve Cohen's Demand

A quick note on the federal front: Rep. Steve Cohen (D-TN) publicly called out the administration this week, tweeting that real progress on marijuana reform has "completely stalled under Trump" despite the December executive order. "Deadlines missed, reforms delayed, and no answers given," Cohen wrote. "I'm demanding answers."

He is not wrong. The executive order was signed December 18. Three and a half months later, the DEA hearing remains stayed, the judge is gone, and the DOJ has provided no public update on the timeline.

Sixteen days to 4/20. Nine days until New Jersey. The markets are bleeding. The science keeps building. And the process remains frozen.